Education
About Us
Working with TipRanks
Follow Us
Ascentage Pharma Group International (HK:6855)
:6855
Total Valuation
Ascentage Pharma Group International has a market cap or net worth of HK$28.98B. The enterprise value is HK$26.20B.
Market CapHK$28.98B
Enterprise ValueHK$26.20B
Share Statistics
Ascentage Pharma Group International has 372,671,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding372,671,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ascentage Pharma Group International’s return on equity (ROE) is -1.53 and return on invested capital (ROIC) is -17.43%.
Return on Equity (ROE)-1.53
Return on Assets (ROA)-0.15
Return on Invested Capital (ROIC)-17.43%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee1.73M
Profits Per Employee-715.05K
Employee Count567
Asset Turnover0.37
Inventory Turnover4.41
Valuation Ratios
The current PE Ratio of Ascentage Pharma Group International is ―. Ascentage Pharma Group International’s PEG ratio is 0.54.
PE Ratio―
PS Ratio13.15
PB Ratio48.81
Price to Fair Value48.81
Price to FCF-95.06
Price to Operating Cash Flow-63.19
PEG Ratio0.54
Income Statement
In the last 12 months, Ascentage Pharma Group International had revenue of 980.65M and earned -405.43M in profits. Earnings per share was -1.34.
Revenue980.65M
Gross Profit951.57M
Operating Income-378.80M
Pretax Income-395.25M
Net Income-405.43M
EBITDA-299.63M
Earnings Per Share (EPS)-1.34
Cash Flow
In the last 12 months, operating cash flow was -189.09M and capital expenditures -27.80M, giving a free cash flow of -216.89M billion.
Operating Cash Flow-189.09M
Free Cash Flow-216.89M
Free Cash Flow per Share-0.58
Dividends & Yields
Ascentage Pharma Group International pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change83.08%
50-Day Moving Average79.62
200-Day Moving Average56.48
Relative Strength Index (RSI)48.48
Average Volume (3m)3.10M
Important Dates
Ascentage Pharma Group International upcoming earnings date is Apr 1, 2026, TBA (Confirmed).
Last Earnings DateAug 20, 2025
Next Earnings DateApr 1, 2026
Ex-Dividend Date―
Financial Position
Ascentage Pharma Group International as a current ratio of 1.26, with Debt / Equity ratio of 631.54%
Current Ratio1.26
Quick Ratio1.26
Debt to Market Cap0.13
Net Debt to EBITDA-1.36
Interest Coverage Ratio-5.88
Taxes
In the past 12 months, Ascentage Pharma Group International has paid 10.43M in taxes.
Income Tax10.43M
Effective Tax Rate-0.03
Enterprise Valuation
Ascentage Pharma Group International EV to EBITDA ratio is -44.39, with an EV/FCF ratio of -98.06.
EV to Sales13.56
EV to EBITDA-44.39
EV to Free Cash Flow-98.06
EV to Operating Cash Flow-119.45
Balance Sheet
Ascentage Pharma Group International has HK$1.66B in cash and marketable securities with HK$1.72B in debt, giving a net cash position of -HK$54.71M billion.
Cash & Marketable SecuritiesHK$1.66B
Total DebtHK$1.72B
Net Cash-HK$54.71M
Net Cash Per Share-HK$0.15
Tangible Book Value Per ShareHK$0.57
Margins
Gross margin is 97.03%, with operating margin of -38.63%, and net profit margin of -41.34%.
Gross Margin97.03%
Operating Margin-38.63%
Pretax Margin-40.31%
Net Profit Margin-41.34%
EBITDA Margin-30.55%
EBIT Margin-38.63%
Analyst Forecast
The average price target for Ascentage Pharma Group International is HK$93.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$93.00
Price Target Upside21.09% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-56.94%
EPS Growth Forecast-190.36%